Exploring the role of targeted radiopharmaceutical treatment in NETs

How are advances in radioligand therapy shaping the treatment of neuroendocrine tumours, and what does recent trial evidence tell us? What are the key considerations for patient selection, sequencing, and safety?  In this podcast moderated by the Oncology Brothers, Drs Rohit and Rahul Gosain are joined by medical oncologist Dr Heloisa Soares and nuclear medicine physician Prof. Ken Herrmann to explore the evolving role of targeted radioligand therapy in NETs.  As the conversation unfolds, the experts discuss evidence from recent studies, including the COMPETE trial, share practical insights on multidisciplinary decision-making, and highlight future directions such as the potential for first-line treatment with radioligand therapy.  Key clinical takeaways:   Pair the right patient with the right treatment using an understanding of the key clinical studies  The role of PRRT as a very effective 2nd-line treatment was consolidated by the COMPETE study data   The best outcomes are achieved through multi-disciplinary collaborations that include the patient     Listen to the audio version of this conversation on Spotify, Apple, or on the COR2ED website, where you can also download the accompanying transcript and infographic: https://cor2ed.com/net-connect/programmes/targeted-radiopharmaceutical-treatment-nets/?media=0   Follow us on social media:  LinkedIn: https://www.linkedin.com/company/cor2ed-net-connect/?viewAsMember=true   X: https://x.com/net_connectinfo   This content is intended for healthcare professionals only.  This podcast is supported by an Independent Education Grant from ITM.   This podcast is developed by cor2ed.com    Published September 2025